渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BIIB 渤健公司

休市中 08-23 16:00:00 EDT

205.00

+1.68

+0.83%

盘后205.00

+0.000.00%

19:42 EDT

最高205.54	最低202.13	成交量112.74万
今开204.50	昨收203.32	日振幅1.68%
总市值298.61亿	流通市值297.51亿	总股本1.46亿
成交额2.30亿	换手率0.78%	流通股本1.45亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"BIIB","market":"US","secType":"STK","nameCN":"渤健公司","latestPrice":205,"timestamp":1724443200000,"preClose":203.32,"halted":0,"volume":1127364,"hourTrading":{"tag":"盘后","latestPrice":205,"preClose":205,"latestTime":"19:42 EDT","volume":31053,"amount":6366145.8564,"timestamp":1724456536126},"delay":0,"floatShares":145127049,"shares":145661642,"eps":7.93943,"marketStatus":"休市中","marketStatusCode":7,"change":1.68,"latestTime":"08-23 16:00:00 EDT","open":204.5,"high":205.54,"low":202.13,"amount":230397982.74864,"amplitude":0.016772,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":7.93943,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1724659200000},"adr":0,"listingDate":685080000000,"adjPreClose":203.32,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":204.39,"preClose":203.32,"latestTime":"09:29 EDT","volume":5841,"amount":1190369.28186,"timestamp":1724419799960},"postHourTrading":{"tag":"盘后","latestPrice":205,"preClose":205,"latestTime":"19:42 EDT","volume":31053,"amount":6366145.8564,"timestamp":1724456536126},"volumeRatio":1.6021772894084072,"impliedVol":0.2541,"impliedVolPercentile":0.0754},"requestUrl":"/m/hq/s/BIIB/tweets","defaultTab":"tweets","newsList":[{"id":"2461346324","title":"BUZZ-英国定价监督机构认为百健公司阿尔茨海默氏症新药价格昂贵，导致百健公司股价下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2461346324","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461346324?lang=zh_cn&edition=full","pubTime":"2024-08-22 22:38","pubTimestamp":1724337498,"startTime":"0","endTime":"0","summary":"    8月22日 - ** 百健  股价下跌1.3%，至203.45美元** 英国卫生监管机构批准了BIIB和合作伙伴卫材  的药物Leqembi，使其成为英国首个获准使用的阿尔茨海默病治疗药物 ** 然而，英国成本效益机构--国家健康与护理卓越研究所表示，这种药物的成本较高，而且需要对副作用进行强化监测，\"这意味着它不能被视为对纳税人来说物有所值的药物\"。** 包括盘中走势在内，该股今年累计下跌约 21","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK4532","LU0889565916.HKD","IE00B19Z9Z06.USD","BK4533","IE00B19Z9P08.USD","BK4588","BUZZ","BIIB","IE00B894F039.SGD","LU0109394709.USD","LU0234570918.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2461318747","title":"百健(BIIB.US)及卫材(ESALF.US)旗下阿尔茨海默症药物Leqembi在英国获得上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2461318747","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461318747?lang=zh_cn&edition=full","pubTime":"2024-08-22 19:30","pubTimestamp":1724326253,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百健及其日本合作伙伴卫材周四宣布，旗下突破性阿尔茨海默症治疗药物Leqembi 已在英国获得营销许可，英国成为欧洲第一个批准该药物的国家。2024年1月，中国批准了Leqembi作为治疗阿尔茨海默症引起的轻度认知障碍和轻度痴呆的药物，成为继美国和日本之后第三个批准Leqembi的国家。随着百健主打的多发性硬化症药物销量下滑，该公司正寻求提振Leqembi的销量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408221936199f47d874&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408221936199f47d874&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","IE00B894F039.SGD","BK4585","LU0109394709.USD","IE00B19Z9Z06.USD","BK4532","BIIB","BK4139","BK4007","LU0234570918.USD","ESALF","IE00B19Z9P08.USD","LU0889565916.HKD","LU0320765992.SGD","BK4533"],"gpt_icon":0},{"id":"2461959483","title":"更新版 1-老年痴呆症新药被认为对英国国家医疗服务系统患者来说过于昂贵","url":"https://stock-news.laohu8.com/highlight/detail?id=2461959483","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461959483?lang=zh_cn&edition=full","pubTime":"2024-08-22 17:43","pubTimestamp":1724319836,"startTime":"0","endTime":"0","summary":"     路透8月22日 - 英国国营医疗服务机构的阿尔茨海默氏症患者不太可能获得卫材  和百健  的新药Leqembi，因为该药已于周四获得该国监管机构的批准，但被认为过于昂贵，不适合广泛使用。药品和保健品监管局 称，这种也被称为Lecanemab的药物是第一种获准在该国使用的阿尔茨海默氏症治疗药物，\"有证据表明它在延缓疾病进展方面具有一定疗效\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","IE00B19Z9Z06.USD","LU0234570918.USD","BK4588","LU0320765992.SGD","LU0109394709.USD","IE00B894F039.SGD","BK4139","BIIB","IE00B19Z9P08.USD","BK4585","BK4533","BK4532"],"gpt_icon":0},{"id":"2461360891","title":"英国患者不可能获得卫材-百健的阿尔茨海默氏症药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2461360891","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461360891?lang=zh_cn&edition=full","pubTime":"2024-08-22 17:00","pubTimestamp":1724317239,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透8月22日 - 英国国营医疗服务机构的阿尔茨海默氏症患者不太可能获得卫材  和百健  的新药Leqembi，因为该药已于周四获得该国监管机构的批准，但被认为过于昂贵，不适合广泛使用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK4588","BK4532","LU0234570918.USD","BK4585","BK4139","IE00B19Z9P08.USD","BIIB","BK4533","IE00B19Z9Z06.USD","IE00B894F039.SGD","LU0320765992.SGD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2461386487","title":"媒体-卫材和百健的阿尔茨海默氏症药物将在英国获批 - 每日电讯报","url":"https://stock-news.laohu8.com/highlight/detail?id=2461386487","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461386487?lang=zh_cn&edition=full","pubTime":"2024-08-22 08:21","pubTimestamp":1724286104,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    8月22日 - -- 来源链接：  -- 注：路透未核实此报导，不保证其准确性","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4533","BK4588","IE00B19Z9P08.USD","BK4585","LU0889565916.HKD","IE00B19Z9Z06.USD","BK4532","LU0234570918.USD","BIIB","IE00B894F039.SGD","LU0109394709.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2459281046","title":"Incyte公司血癌药物后期试验取得成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2459281046","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459281046?lang=zh_cn&edition=full","pubTime":"2024-08-16 07:03","pubTimestamp":1723763025,"startTime":"0","endTime":"0","summary":"    路透8月15日 - Incyte公司  周四说，它的药物在一项晚期试验中达到了主要目标，该试验对一种血癌患者进行了评估。该公司说，它的药物Monjuvi与百时美施贵宝  的药物Revlimid和百健  的Rituxan联合使用，与单独使用Rituxan和Revlimid相比，滤泡性淋巴瘤患者的无进展生存期。Monjuvi 与Revlimid联合用药已被批准用于治疗弥漫性大B细胞淋巴瘤，这也是非霍奇金淋巴瘤的一种亚型。根据这项试验的结果，Incyte 预计将在今年年底前向 FDA 提交补充上市申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242652126.USD","LU0306807586.USD","BK4566","BK4585","BIIB","BMY","IE00B19Z9Z06.USD","BK4550","LU2242646821.SGD","BK4581","IE00B894F039.SGD","LU1291159041.SGD","LU1670711040.USD","IE0002141913.USD","LU0234570918.USD","IE00BSNM7G36.USD","LU2125154935.USD","IE00BFTCPJ56.SGD","FL","IE00B2B36J28.USD","LU1430594728.SGD","LU2087621335.USD","INCY","LU0109394709.USD","LU0306806265.USD","LU1032466523.USD","LU0889565916.HKD","LU2125154778.USD","LU2133065610.SGD","LU0225284248.USD","IE00BZ1G4Q59.USD","LU1670711123.USD","LU1839511570.USD","IE0009355771.USD","BK4568","GILD","BK4588","BK4139","BK4578","LU1066053197.SGD","LU2360032135.SGD","LU0114720955.EUR","IE00BKVL7J92.USD","LU1718418525.SGD","LU1670710661.SGD","LU1670710588.SGD","LU0321505439.SGD","LU0985481810.HKD","LU0456855351.SGD","LU1074936037.SGD"],"gpt_icon":0},{"id":"2459953772","title":"渤健公司跌0.99% 股价跌破200美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2459953772","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459953772?lang=zh_cn&edition=full","pubTime":"2024-08-13 03:23","pubTimestamp":1723490592,"startTime":"0","endTime":"0","summary":"北京时间2024年08月13日03时23分，渤健公司股票出现异动，股价大幅下挫0.99%。截至发稿，该股报200.00美元/股，成交量44.5837万股，换手率0.31%，振幅1.47%。渤健公司股票所在的制药行业中，整体跌幅为0.49%。渤健公司公司简介：Biogen和Idec于2003年合并，联手销售Biogen的多发性硬化症药物Avonex和Idec的癌症药物Rituxan。Biogen销售多种多发性硬化症药物，包括Plegridy、Tysabri、Tecfidera和Vumerity。Biogen在神经学、免疫学和罕见病方面有几种候选药物正在进行三期试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240813032312af9719ad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240813032312af9719ad&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4533","BK4532","LU0889565916.HKD","IE00B19Z9P08.USD","LU0109394709.USD","LU0234570918.USD","BK4585","BIIB","IE00B19Z9Z06.USD","BK4139","IE00B894F039.SGD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2458684726","title":"渤健公司2024财年第二财季实现净利润5.84亿美元，同比减少1.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2458684726","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458684726?lang=zh_cn&edition=full","pubTime":"2024-08-11 00:12","pubTimestamp":1723306324,"startTime":"0","endTime":"0","summary":"8月11日，渤健公司公布财报，公告显示公司2024财年第二财季净利润为5.84亿美元，同比减少1.35%；其中营业收入为23.53亿美元，同比增加0.09%，每股基本收益为4.01美元。从资产负债表来看，渤健公司总负债109.15亿美元，其中短期债务1.93亿美元，资产负债比为2.46，流动比率为2.29。机构评级：截至2024年8月11日，当前有27家机构对渤健公司目标价做出预测，其中目标均价为270.63美元，其中最低目标价为190.00美元，最高目标价为342.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408110012169f204529&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408110012169f204529&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BIIB"],"gpt_icon":0},{"id":"2458922518","title":"BUZZ-杰富瑞：百健-艾赛的老年痴呆症药物销售恢复 \"良好增长势头","url":"https://stock-news.laohu8.com/highlight/detail?id=2458922518","media":"Reuters","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458922518?lang=zh_cn&edition=full","pubTime":"2024-08-09 23:44","pubTimestamp":1723218283,"startTime":"0","endTime":"0","summary":"    8月9日 - ** 券商杰富瑞援引医疗保健数据和分析公司Symphony的数据称，百健  和卫材  的阿尔茨海默氏症药物Leqembi在7月份的销售额为1350万美元。** 礼来公司的  阿尔茨海默氏症药物Kinsula于7月2日获得批准，上市首月销售额为12.2万美元--Jefferies** 销售额意味着 7 月份有 45-55 名患者接受了 Kisunla 治疗--券商** 总体而言，我们仍然认为有两种药物上市对 BIIB/Eisai 有利，因为我们预计会分配更多资源来解决各种上市行政障碍 - 杰富瑞证券","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","LU0882574139.USD","LU0889565916.HKD","IE00B19Z9P08.USD","BK4127","LU0289739699.SGD","LU0943347566.SGD","BK4516","LU1623119135.USD","JEF","IE00B1BXHZ80.USD","GB00BDT5M118.USD","LU0882574055.USD","LU0109391861.USD","LU0094547139.USD","LU0061475181.USD","BK4007","BK4534","BIIB","LU0114720955.EUR","LU1551013425.SGD","LU0006306889.USD","LU0385154629.USD","LU0689472784.USD","LU1280957306.USD","BUZZ","LU0320765992.SGD","IE00BJJMRZ35.SGD","LU0256863811.USD","IE00BJT1NW94.SGD","IE00BJLML261.HKD","LU0122379950.USD","LU1061106388.HKD","BK4585","IE0002141913.USD","LU0097036916.USD","LU0708995401.HKD","LU0820561909.HKD","LU0079474960.USD","LU0058720904.USD","BK4533","LU1069344957.HKD","LU0096364046.USD","LU1035775433.USD","LU1057294990.SGD","LU1551013342.USD","IE0004445239.USD","LU1023059063.AUD","LU0471298694.HKD"],"gpt_icon":1},{"id":"2458599658","title":"渤健公司跌2.04% 股价跌破200美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2458599658","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458599658?lang=zh_cn&edition=full","pubTime":"2024-08-09 21:46","pubTimestamp":1723211203,"startTime":"0","endTime":"0","summary":"北京时间2024年08月09日21时46分，渤健公司股票出现异动，股价快速下挫2.04%。截至发稿，该股报199.90美元/股，成交量3.662万股，换手率0.03%，振幅2.14%。最近的财报数据显示，该股实现营业收入23.53亿美元，净利润5.84亿美元，每股收益4.01美元，毛利16.48亿美元，市盈率25.25倍。渤健公司股票所在的制药行业中，整体涨幅为2.86%。渤健公司公司简介：Biogen和Idec于2003年合并，联手销售Biogen的多发性硬化症药物Avonex和Idec的癌症药物Rituxan。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240809214644aefe2652&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240809214644aefe2652&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BIIB","LU0234570918.USD","IE00B894F039.SGD","IE00B19Z9Z06.USD","LU0109394709.USD","BK4585","IE00B19Z9P08.USD","LU0889565916.HKD","BK4533","BK4139","BK4588","LU0320765992.SGD","BK4532"],"gpt_icon":0},{"id":"2457193313","title":"渤健公司涨0.22% 股价突破200美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2457193313","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457193313?lang=zh_cn&edition=full","pubTime":"2024-08-08 21:33","pubTimestamp":1723124015,"startTime":"0","endTime":"0","summary":"北京时间2024年08月08日21时33分，渤健公司股票出现波动，股价急速拉升0.22%。截至发稿，该股报200.22美元/股，成交量1.1553万股，换手率0.01%，振幅0.17%。渤健公司股票所在的制药行业中，整体涨幅为6.69%。渤健公司公司简介：Biogen和Idec于2003年合并，联手销售Biogen的多发性硬化症药物Avonex和Idec的癌症药物Rituxan。Biogen在神经学、免疫学和罕见病方面有几种候选药物正在进行三期试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240808213336968252b1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240808213336968252b1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0234570918.USD","BK4585","LU0109394709.USD","LU0889565916.HKD","LU0320765992.SGD","BIIB","IE00B19Z9P08.USD","BK4588","IE00B19Z9Z06.USD","IE00B894F039.SGD","BK4532","BK4533","BK4139"],"gpt_icon":0},{"id":"2457044026","title":"美国研究综述-Actinium Pharmaceuticals、Albemarle、ArcBest","url":"https://stock-news.laohu8.com/highlight/detail?id=2457044026","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457044026?lang=zh_cn&edition=full","pubTime":"2024-08-06 20:56","pubTimestamp":1722949016,"startTime":"0","endTime":"0","summary":"    路透8月6日 - 华尔街证券分析师周二调整了对几家美国上市公司的评级和目标价，其中包括 Actinium Pharmaceuticals、Albemarle 和 ArcBest。要点   * Actinium Pharmaceuticals Inc   ：JonesTrading将其交易价格从26美元下调至9美元 * Albemarle   ：Baird将其评级下调至中性，目标价从102美元下调至85美元 * ArcBest Corp   ：Stephens 将目标价从 145 美元下调至 130 美元 * Crispr Therapeutics AG   ：Leerink Partners将目标价从80美元下调至68美元 * Warrior Met Coal Inc   ：杰富瑞将目标价从85美元下调至78美元 以下是路透周二报道的美国公司研究行动摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANAB","ASPN","BCRX","BK","BMRN","CABO","ALHC","LU1323610961.USD","AHR","BK4129","ALB","ADUS","LNT","LU1978683503.SGD","AMWL","CDNS","ARCH","LU0648001328.SGD","BK4231","BKH","IE00BKDWB100.SGD","AEE","CBT","AXSM","AEP","BIIB","BK4519","AN","AKYA","APO","AQMS","AES","ALL","ETNB","LU0354030511.USD","LU","BN","AMRC","ALX","IE00B1XK9C88.USD","CG","CTRE","ARCB","AIG","ATIP","CWT"],"gpt_icon":1},{"id":"2457067107","title":"渤健公司：瑞穗将目标价从277美元下调至251美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2457067107","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457067107?lang=zh_cn&edition=full","pubTime":"2024-08-06 14:49","pubTimestamp":1722926988,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","IE00B894F039.SGD","BK4588","BK4532","LU0109394709.USD","BK4533","BK4585","IE00B19Z9Z06.USD","IE00B19Z9P08.USD","LU0234570918.USD","LU0320765992.SGD","LU0889565916.HKD","BIIB"],"gpt_icon":0},{"id":"2457778153","title":"渤健公司跌3.24% 股价跌破200美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2457778153","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457778153?lang=zh_cn&edition=full","pubTime":"2024-08-05 21:40","pubTimestamp":1722865247,"startTime":"0","endTime":"0","summary":"北京时间2024年08月05日21时40分，渤健公司股票出现异动，股价急速下跌3.24%。截至发稿，该股报199.00美元/股，成交量8.6498万股，换手率0.06%，振幅2.21%。渤健公司股票所在的制药行业中，整体跌幅为2.38%。渤健公司公司简介：Biogen和Idec于2003年合并，联手销售Biogen的多发性硬化症药物Avonex和Idec的癌症药物Rituxan。消息层面，截至21时40分，渤健公司股票正面舆情新闻比例25%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240805214047aefd4cdc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240805214047aefd4cdc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B894F039.SGD","BIIB","LU0320765992.SGD","IE00B19Z9P08.USD","LU0889565916.HKD","IE00B19Z9Z06.USD","BK4533","BK4532","LU0109394709.USD","BK4139","LU0234570918.USD","BK4588","BK4585"],"gpt_icon":0},{"id":"2457239737","title":"渤健公司：Truist Securities将目标价从340美元下调至302美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2457239737","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457239737?lang=zh_cn&edition=full","pubTime":"2024-08-05 19:21","pubTimestamp":1722856867,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0889565916.HKD","BK4532","IE00B894F039.SGD","BK4533","LU0320765992.SGD","LU0109394709.USD","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","LU0234570918.USD","BK4585","BIIB","BK4139","BK4588"],"gpt_icon":0},{"id":"2457974290","title":"渤健公司：古根海姆将目标价从255美元降至245美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2457974290","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457974290?lang=zh_cn&edition=full","pubTime":"2024-08-05 18:18","pubTimestamp":1722853129,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","BK4533","BK4588","IE00B19Z9P08.USD","BK4585","LU0889565916.HKD","IE00B19Z9Z06.USD","BK4532","LU0234570918.USD","BIIB","IE00B894F039.SGD","LU0109394709.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2457742442","title":"Needham：维持Biogen(BIIB.US)评级，由买入调整至买入评级, 目标价由288.00美元调整至285.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2457742442","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457742442?lang=zh_cn&edition=full","pubTime":"2024-08-05 18:12","pubTimestamp":1722852736,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0234570918.USD","BK4585","LU0109394709.USD","LU0889565916.HKD","LU0320765992.SGD","BIIB","IE00B19Z9P08.USD","BK4588","IE00B19Z9Z06.USD","IE00B894F039.SGD","BK4532","BK4533","BK4139"],"gpt_icon":0},{"id":"2456259572","title":"富国银行：维持Biogen(BIIB.US)评级，由持股观望调整至持股观望评级, 目标价由240.00美元调整至225.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2456259572","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456259572?lang=zh_cn&edition=full","pubTime":"2024-08-03 02:28","pubTimestamp":1722623296,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0889565916.HKD","IE00B19Z9Z06.USD","LU0234570918.USD","BK4588","LU0320765992.SGD","LU0109394709.USD","IE00B894F039.SGD","BK4139","BIIB","IE00B19Z9P08.USD","BK4585","BK4533","BK4532"],"gpt_icon":0},{"id":"2456821772","title":"Wedbush：维持Biogen(BIIB.US)评级，由中性调整至中性评级, 目标价由215.00美元调整至210.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2456821772","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456821772?lang=zh_cn&edition=full","pubTime":"2024-08-02 21:47","pubTimestamp":1722606458,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BIIB","LU0109394709.USD","BK4532","LU0320765992.SGD","LU0889565916.HKD","BK4585","LU0234570918.USD","BK4139","IE00B19Z9Z06.USD","BK4533","BK4588","IE00B894F039.SGD","IE00B19Z9P08.USD"],"gpt_icon":0},{"id":"2456281510","title":"BUZZ-券商观点：看到百健的稳步增长需要耐心","url":"https://stock-news.laohu8.com/highlight/detail?id=2456281510","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456281510?lang=zh_cn&edition=full","pubTime":"2024-08-02 21:40","pubTimestamp":1722606037,"startTime":"0","endTime":"0","summary":"    8月2日 - ** Biogen   周四提高了  年度利润预期，原因是削减了成本，而且其各种治疗药物的销售好于预期，尽管其阿尔茨海默氏症药物在美国的采用仍然缓慢。需要进行收购以建立其产品组合** Needham 称 \"在出现拐点之前仍需耐心等待\"。** 补充说，总体而言，市场希望看到阿尔茨海默氏症加速发展 ** 摩根大通 依然认为近期更有可能进行小型交易，但 2025 年及以后可能会看到百健寻求大型收购。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB","LU0234570918.USD","IE00B894F039.SGD","IE00B19Z9Z06.USD","LU0109394709.USD","BK4585","IE00B19Z9P08.USD","LU0889565916.HKD","BK4533","BK4139","BK4588","BUZZ","LU0320765992.SGD","BK4532"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biogen.com","stockEarnings":[{"period":"1week","weight":0.0153},{"period":"1month","weight":-0.093},{"period":"3month","weight":-0.0588},{"period":"6month","weight":-0.082},{"period":"1year","weight":-0.2188},{"period":"ytd","weight":-0.2078}],"compareEarnings":[{"period":"1week","weight":0.0141},{"period":"1month","weight":0.0386},{"period":"3month","weight":0.0617},{"period":"6month","weight":0.1069},{"period":"1year","weight":0.2867},{"period":"ytd","weight":0.1827}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Biogen Inc.于1985年在加利福尼亚州以IDEC制药公司的名义成立，并于1997年重新注册为特拉华州公司。2003年，他们收购了Biogen, Inc.，并将公司名称更改为Biogen Idec Inc.。该公司是一家全球性的生物制药公司，专注于为患有严重神经和神经退行性疾病的患者以及相关的治疗邻接患者发现、开发和提供全球创新疗法。该公司的核心增长领域包括多发性硬化症（MS）和神经免疫学；阿尔茨海默病（AD）和痴呆症；神经肌肉疾病，包括脊髓肌萎缩症（SMA）和肌萎缩侧索硬化症（ALS）；运动障碍，包括帕金森氏症；以及眼科学。该公司还专注于在免疫学、神经认知障碍、急性神经学和疼痛等新兴增长领域发现、开发和提供全球创新疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.575758,"avgChangeRate":0.042714},{"month":2,"riseRate":0.424242,"avgChangeRate":-0.004267},{"month":3,"riseRate":0.515152,"avgChangeRate":-0.023197},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.018344},{"month":5,"riseRate":0.606061,"avgChangeRate":0.032222},{"month":6,"riseRate":0.484848,"avgChangeRate":0.01808},{"month":7,"riseRate":0.666667,"avgChangeRate":0.035186},{"month":8,"riseRate":0.575758,"avgChangeRate":0.030637},{"month":9,"riseRate":0.5,"avgChangeRate":0.024456},{"month":10,"riseRate":0.545455,"avgChangeRate":0.062497},{"month":11,"riseRate":0.606061,"avgChangeRate":0.016153},{"month":12,"riseRate":0.484848,"avgChangeRate":0.038726}],"exchange":"NASDAQ","name":"渤健公司","nameEN":"Biogen"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供渤健公司(BIIB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"渤健公司,BIIB,渤健公司股票,渤健公司股票老虎,渤健公司股票老虎国际,渤健公司行情,渤健公司股票行情,渤健公司股价,渤健公司股市,渤健公司股票价格,渤健公司股票交易,渤健公司股票购买,渤健公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供渤健公司(BIIB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}